Benjamin Garmezy, MD
Medical Oncologist

Benjamin Garmezy, MD

Specialities

  • Genitourinary cancers, including prostate, kidney, bladder and testicular
  • Clinical trials and research advancements
  • Early-phase drug development
  • Clinical Research

Education

Medical Degree: Baylor College of Medicine
Residency: University of Michigan
Fellowship: University of Texas MD Anderson Cancer Center

Location

335 24th Avenue North, Suite 200  
Nashville, Tennessee 37203 
Phone: 615-329-7640 
Fax: 615-234-7723 

Language

English

Biography

Dr. Garmezy is board-certified in medical oncology, hematology, and internal medicine. He has a special interest in genitourinary cancers, including prostate, kidney, bladder, and testicular cancers. Dr. Garmezy currently sees patients in clinic at SCRI Oncology Partners. He is also the associate director of genitourinary research at SCRI, where he oversees investigational therapy trials. He has served as faculty at numerous meetings including the American Society of Clinical Oncology, the European Society of Medical Oncology, and the International Kidney Cancer Symposium. In addition, he has published many articles and over 50 additional abstracts related to clinical trials and investigation.

Philosophy

Dr. Garmezy strives to guide each patient and their family members with knowledge and compassion throughout their cancer journey. He is proud to be able to offer leading-edge research and the best-emerging treatment options for his patients.

Relevant Research

The Lancet

The Lancet

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study

Oncology and Therapy

Oncology and Therapy

Understanding Treatment Decisions and Management for Patients with Advanced Renal Cell Carcinoma Using Hypothetical Case Studies: A Vodcast

Cancer Research Community

Cancer Research Community

A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors